Abstract
This study evaluated the in vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent. The drug inhibited all tested members of the family Enterobacteriaceae at < or = 0.5 microgram/ml and all tested Pseudomonas aeruginosa, Burkholderia (Pseudomonas) cepacia, and Xanthomonas maltophilia strains at < or = 2 micrograms/ml. All but two strains of gram-positive bacteria were inhibited by < or = 1 microgram of the new drug per ml, including isolates highly resistant to ciprofloxacin.
Full Text
The Full Text of this article is available as a PDF (198.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bingen E. H., Denamur E., Lambert-Zechovsky N. Y., Elion J. Evidence for the genetic unrelatedness of nosocomial vancomycin-resistant Enterococcus faecium strains in a pediatric hospital. J Clin Microbiol. 1991 Sep;29(9):1888–1892. doi: 10.1128/jcm.29.9.1888-1892.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ford A. S., Baltch A. L., Smith R. P., Ritz W. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. J Antimicrob Chemother. 1993 Apr;31(4):523–532. doi: 10.1093/jac/31.4.523. [DOI] [PubMed] [Google Scholar]
- Frieden T. R., Munsiff S. S., Low D. E., Willey B. M., Williams G., Faur Y., Eisner W., Warren S., Kreiswirth B. Emergence of vancomycin-resistant enterococci in New York City. Lancet. 1993 Jul 10;342(8863):76–79. doi: 10.1016/0140-6736(93)91285-t. [DOI] [PubMed] [Google Scholar]
- Uttley A. H., George R. C., Naidoo J., Woodford N., Johnson A. P., Collins C. H., Morrison D., Gilfillan A. J., Fitch L. E., Heptonstall J. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect. 1989 Aug;103(1):173–181. doi: 10.1017/s0950268800030478. [DOI] [PMC free article] [PubMed] [Google Scholar]